SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994.
The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.
SV Life Sciences and Health Enterprise Partners Announce Formation of Jet Health - 15 April 2016
SV Life Sciences Advisers ("SVLS") and Health Enterprise Partners ("HEP") announced today that they have partnered with experienced healthcare services executive Jim Glynn to form Jet Health, Inc. ("Jet Health").
Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering - 3 September 2015
Acquisition Adds Global Rights to XEN45, a Minimally Invasive Best-In-Class Implantable Shunt for Glaucoma --- XEN45 Approved in Global Markets; Late-Stage Development in the US --- Bolsters Allergan's Development and Commercialization Position in Glaucoma